[ad_1]
Representatives of private immunization clinics in Brazil will travel to India to negotiate the purchase of doses of vaccines against covid-19 developed by Bharat Biotech, a local industry in the Asian country.
Geraldo Barbosa, president of ABCVAC (Brazilian Association of Vaccine Clinics), said today, in an interview with GloboNews, that the organization is organizing a delegation to evaluate the company’s plant and “know the real capacity” of the pharmaceutical company, to check the possibility of buying excess doses of the immunizer to supply private clinics.
“We will know if the capacity exists, if not we will create frustrated expectations in the future. But what we have seen so far is that we will have a vaccine available in the private market by 2021, for sure,” Barbosa said.
The Bharat Biotech vaccine received authorization for emergency use in India on Sunday (3), together with that developed by the AstraZeneca laboratory in partnership with the University of Oxford. The immunizer is in phase 3 of the research and depends on the authorization of Anvisa (National Agency for Sanitary Surveillance) for its use in Brazil.
According to the representative of the private clinics, the entity signed a term of purchase intention for five million initial doses: “It is the amount they had to offer at this time. We are fighting for a little more, but at first the forecast is five million. ” dose “.
The vaccine, according to Barbosa, will not arrive ready and will depend on supplies, syringes and needles. The president of ABCVAC said that he does not believe that the private chain offers competition for the immunization program in the public chain, considering the dispute over this raw material. “It is already in our business to have a needle and a syringe, it is already our routine stock,” he argued.
